Bellicum Pharmaceuticals (FRA:BPXA) EBIT per Share : €-0.72 (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals EBIT per Share?

Bellicum Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2023 was €-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.72.

During the past 3 years, the average EBIT per Share Growth Rate was 63.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 51.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Bellicum Pharmaceuticals's EBIT per Share or its related term are showing as below:

FRA:BPXA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.6 Med: 15.95 Max: 63.9
Current: 63.9

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Bellicum Pharmaceuticals was 63.90% per year. The lowest was -46.60% per year. And the median was 15.95% per year.

FRA:BPXA's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.4 vs FRA:BPXA: 63.90

Bellicum Pharmaceuticals's EBIT for the three months ended in Sep. 2023 was €-0.73 Mil.

Bellicum Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Bellicum Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals EBIT per Share Chart

Bellicum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-20.50

-20.79

-0.72

-1.88

-0.83

Bellicum Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-0.24	-0.23	-0.26	-0.21	-0.02

Bellicum Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Bellicum Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.47	/	30.828
=	-0.83

Bellicum Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.725	/	30.905
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.72

Bellicum Pharmaceuticals (FRA:BPXA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Bellicum Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellicum Pharmaceuticals (FRA:BPXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (FRA:BPXA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BLCM:USA

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (FRA:BPXA) Headlines

No Headlines